vs
Pediatrix Medical Group, Inc.（MD）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
Pediatrix Medical Group, Inc.的季度营收约是ROYAL GOLD INC的1.3倍（$493.8M vs $375.3M），ROYAL GOLD INC净利率更高（24.9% vs 6.8%，领先18.1%），ROYAL GOLD INC同比增速更快（85.3% vs -1.7%），过去两年ROYAL GOLD INC的营收复合增速更高（58.8% vs -0.1%）
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
MD vs RGLD — 直观对比
营收规模更大
MD
是对方的1.3倍
$375.3M
营收增速更快
RGLD
高出87.0%
-1.7%
净利率更高
RGLD
高出18.1%
6.8%
两年增速更快
RGLD
近两年复合增速
-0.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $493.8M | $375.3M |
| 净利润 | $33.7M | $93.6M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 9.9% | 56.2% |
| 净利率 | 6.8% | 24.9% |
| 营收同比 | -1.7% | 85.3% |
| 净利润同比 | 10.5% | -12.8% |
| 每股收益（稀释后） | $0.40 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MDRGLD
| Q4 25 | $493.8M | $375.3M | ||
| Q3 25 | $492.9M | $252.1M | ||
| Q2 25 | $468.8M | $209.6M | ||
| Q1 25 | $458.4M | $193.4M | ||
| Q4 24 | $502.4M | $202.6M | ||
| Q3 24 | $511.2M | $193.8M | ||
| Q2 24 | $504.3M | $174.1M | ||
| Q1 24 | $495.1M | $148.9M |
净利润MDRGLD
| Q4 25 | $33.7M | $93.6M | ||
| Q3 25 | $71.7M | $126.8M | ||
| Q2 25 | $39.3M | $132.3M | ||
| Q1 25 | $20.7M | $113.5M | ||
| Q4 24 | $30.5M | $107.4M | ||
| Q3 24 | $19.4M | $96.2M | ||
| Q2 24 | $-153.0M | $81.2M | ||
| Q1 24 | $4.0M | $47.2M |
毛利率MDRGLD
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 73.6% | ||
| Q2 25 | — | 72.6% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 70.3% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | — | 64.7% | ||
| Q1 24 | — | 58.4% |
营业利润率MDRGLD
| Q4 25 | 9.9% | 56.2% | ||
| Q3 25 | 13.8% | 64.4% | ||
| Q2 25 | 12.8% | 67.7% | ||
| Q1 25 | 7.0% | 63.6% | ||
| Q4 24 | 7.8% | 65.9% | ||
| Q3 24 | 6.6% | 61.3% | ||
| Q2 24 | -31.3% | 58.6% | ||
| Q1 24 | 3.2% | 50.7% |
净利率MDRGLD
| Q4 25 | 6.8% | 24.9% | ||
| Q3 25 | 14.5% | 50.3% | ||
| Q2 25 | 8.4% | 63.1% | ||
| Q1 25 | 4.5% | 58.7% | ||
| Q4 24 | 6.1% | 53.0% | ||
| Q3 24 | 3.8% | 49.7% | ||
| Q2 24 | -30.3% | 46.6% | ||
| Q1 24 | 0.8% | 31.7% |
每股收益（稀释后）MDRGLD
| Q4 25 | $0.40 | $1.04 | ||
| Q3 25 | $0.84 | $1.92 | ||
| Q2 25 | $0.46 | $2.01 | ||
| Q1 25 | $0.24 | $1.72 | ||
| Q4 24 | $0.37 | $1.63 | ||
| Q3 24 | $0.23 | $1.46 | ||
| Q2 24 | $-1.84 | $1.23 | ||
| Q1 24 | $0.05 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $375.2M | $233.7M |
| 总债务越低越好 | $570.5M | — |
| 股东权益账面价值 | $865.9M | $7.2B |
| 总资产 | $2.2B | $9.5B |
| 负债/权益比越低杠杆越低 | 0.66× | — |
8季度趋势，按日历期对齐
现金及短期投资MDRGLD
| Q4 25 | $375.2M | $233.7M | ||
| Q3 25 | $340.1M | $172.8M | ||
| Q2 25 | $224.7M | $248.2M | ||
| Q1 25 | $99.0M | $240.8M | ||
| Q4 24 | $229.9M | $195.5M | ||
| Q3 24 | $103.8M | $127.9M | ||
| Q2 24 | $19.4M | $74.2M | ||
| Q1 24 | $8.0M | $137.9M |
总债务MDRGLD
| Q4 25 | $570.5M | — | ||
| Q3 25 | $577.2M | — | ||
| Q2 25 | $583.9M | — | ||
| Q1 25 | $590.5M | — | ||
| Q4 24 | $597.1M | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益MDRGLD
| Q4 25 | $865.9M | $7.2B | ||
| Q3 25 | $890.7M | $3.4B | ||
| Q2 25 | $833.8M | $3.3B | ||
| Q1 25 | $789.2M | $3.2B | ||
| Q4 24 | $764.9M | $3.1B | ||
| Q3 24 | $732.5M | $3.0B | ||
| Q2 24 | $706.5M | $3.0B | ||
| Q1 24 | $856.2M | $2.9B |
总资产MDRGLD
| Q4 25 | $2.2B | $9.5B | ||
| Q3 25 | $2.2B | $4.5B | ||
| Q2 25 | $2.1B | $3.6B | ||
| Q1 25 | $2.0B | $3.5B | ||
| Q4 24 | $2.2B | $3.4B | ||
| Q3 24 | $2.1B | $3.3B | ||
| Q2 24 | $2.0B | $3.3B | ||
| Q1 24 | $2.2B | $3.3B |
负债/权益比MDRGLD
| Q4 25 | 0.66× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.75× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.1M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 3.39× | 2.58× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流MDRGLD
| Q4 25 | $114.1M | $241.7M | ||
| Q3 25 | $137.3M | $174.0M | ||
| Q2 25 | $137.2M | $152.8M | ||
| Q1 25 | $-117.5M | $136.4M | ||
| Q4 24 | $133.0M | $141.1M | ||
| Q3 24 | $91.8M | $136.7M | ||
| Q2 24 | $107.0M | $113.5M | ||
| Q1 24 | $-125.2M | $138.3M |
现金转化率MDRGLD
| Q4 25 | 3.39× | 2.58× | ||
| Q3 25 | 1.91× | 1.37× | ||
| Q2 25 | 3.49× | 1.15× | ||
| Q1 25 | -5.66× | 1.20× | ||
| Q4 24 | 4.36× | 1.31× | ||
| Q3 24 | 4.72× | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | -31.03× | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
